RPRX
Royalty Pharma plc
Biotechnology · Healthcare · United States
58.56
close · 2026-08-13
value
64
cheaper than peers64
quality
61
stronger fundamentals61
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| forward P/E | 10.21× | 84 |
| price to book | 3.77× | 62 |
| EV to EBITDA | 23.34× | 50 |
| price to sales | 13.21× | 49 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 19.7% | 82 |
| return on equity | 14.0% | 78 |
| revenue growth | 16.5% | 40 |
| debt to equity | 91.6% | 25 |
4 of 4 measures available
Facts
| market cap | $34B |
| free cash flow | -$1.20B |
| employees | 100 |
| first trade | 2020-06-16 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-10 |